Sam Brusco, Associate Editor11.01.22
Roche announced plans to launch its new cobas 5800 system in the U.S. The compact, automated molecular laboratory instrument offers a flexible PCR testing solution to help diagnose infectious diseases.
The company also earned U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its cobas HIV-1 assay. The new system and assay will become available in the fourth quarter of this year.
The cobas 5800 will bring a shared clinical menu of molecular diagnostics testing capabilities to smaller and mid-size labs, and flexibility to larger labs that may use cobas 6800/8800 or systems from other vendors. Its fully automated workflow encompasses sample transfer and preparation, amplification and detection, result calculation and delivery to the laboratory information system. Designed as one integrated instrument, the cobas 5800 System enables a walkaway time of up to eight hours.
The cobas 5800 System has expanded on board capacity, permitting labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift.
"We are pleased to provide the cobas 5800 to expand our molecular portfolio with a flexible solution to meet the needs of labs and health systems serving communities throughout the U.S.," Matt Sause, president and CEO of Roche Diagnostics North America told the press. "The new system furthers our commitment to improve patient care by broadening access to high quality test results so clinicians can make the best treatment decisions for their patients."
The company also earned U.S. Food and Drug Administration (FDA) premarket approval (PMA) for its cobas HIV-1 assay. The new system and assay will become available in the fourth quarter of this year.
The cobas 5800 will bring a shared clinical menu of molecular diagnostics testing capabilities to smaller and mid-size labs, and flexibility to larger labs that may use cobas 6800/8800 or systems from other vendors. Its fully automated workflow encompasses sample transfer and preparation, amplification and detection, result calculation and delivery to the laboratory information system. Designed as one integrated instrument, the cobas 5800 System enables a walkaway time of up to eight hours.
The cobas 5800 System has expanded on board capacity, permitting labs to test multiple assays simultaneously and delivers up to 144 results in an eight-hour shift.
"We are pleased to provide the cobas 5800 to expand our molecular portfolio with a flexible solution to meet the needs of labs and health systems serving communities throughout the U.S.," Matt Sause, president and CEO of Roche Diagnostics North America told the press. "The new system furthers our commitment to improve patient care by broadening access to high quality test results so clinicians can make the best treatment decisions for their patients."